Pharmacologic Immunosuppression at Start of AdV DNAemia, at Start and at the End of Treatment With BCV
| Patient Number . | Pharmacologic Immunosuppression . | . | . |
|---|---|---|---|
| . | At Start of AdV DNAemia . | At Start of Treatment With BCV . | At the End of Treatment With BCV . |
| 1 | None (already positive pretransplant) | CsA (trough 115 µg/L) | CsA (trough 97 µg/L), prednisone |
| 2 | CsA (trough 130 µg/L), MMF, budesonide, prednisone | CsA (trough 87 µg/L), MMF, prednisone, budesonide, methylprednisolone pulse (first of 3 consecutive days) | CsA (trough 67 µg/L), MMF, prednisone, budesonide |
| 3 | CsA (trough 84 µg/L), MMF | everolimus (trough 7.3 µg/L), MMF, prednisone | CsA (trough, 46 µg/L), MMF, prednisone |
| 4 | CsA (trough 103 µg/L) | CsA (trough 46 µg/L) | CsA (trough 46 µg/L) |
| 5 | MMF | MMF | None |
| 6 | CsA (trough 140 µg/L), MMF, prednisone | CsA (trough 101 µg/L), prednisone | None |
| 7 | Everolimus (trough 4.8 µg/L), MMF | None | None |
| 8 | Everolimus (trough 5.4 µg/L), MMF, prednisone | Everolimus (trough 4.3 µg/L), MMF, prednisone | Everolimus (trough 2.4 µg/L), MMF, prednisone, methylprednisolone pulse (second of 3 consecutive days), ruxolitinib |
| Patient Number . | Pharmacologic Immunosuppression . | . | . |
|---|---|---|---|
| . | At Start of AdV DNAemia . | At Start of Treatment With BCV . | At the End of Treatment With BCV . |
| 1 | None (already positive pretransplant) | CsA (trough 115 µg/L) | CsA (trough 97 µg/L), prednisone |
| 2 | CsA (trough 130 µg/L), MMF, budesonide, prednisone | CsA (trough 87 µg/L), MMF, prednisone, budesonide, methylprednisolone pulse (first of 3 consecutive days) | CsA (trough 67 µg/L), MMF, prednisone, budesonide |
| 3 | CsA (trough 84 µg/L), MMF | everolimus (trough 7.3 µg/L), MMF, prednisone | CsA (trough, 46 µg/L), MMF, prednisone |
| 4 | CsA (trough 103 µg/L) | CsA (trough 46 µg/L) | CsA (trough 46 µg/L) |
| 5 | MMF | MMF | None |
| 6 | CsA (trough 140 µg/L), MMF, prednisone | CsA (trough 101 µg/L), prednisone | None |
| 7 | Everolimus (trough 4.8 µg/L), MMF | None | None |
| 8 | Everolimus (trough 5.4 µg/L), MMF, prednisone | Everolimus (trough 4.3 µg/L), MMF, prednisone | Everolimus (trough 2.4 µg/L), MMF, prednisone, methylprednisolone pulse (second of 3 consecutive days), ruxolitinib |
Abbreviations: AdV, adenovirus; BCV, brincidofovir; CsA, cyclosporin A; MMF, mycophenolate mofetil.
Pharmacologic Immunosuppression at Start of AdV DNAemia, at Start and at the End of Treatment With BCV
| Patient Number . | Pharmacologic Immunosuppression . | . | . |
|---|---|---|---|
| . | At Start of AdV DNAemia . | At Start of Treatment With BCV . | At the End of Treatment With BCV . |
| 1 | None (already positive pretransplant) | CsA (trough 115 µg/L) | CsA (trough 97 µg/L), prednisone |
| 2 | CsA (trough 130 µg/L), MMF, budesonide, prednisone | CsA (trough 87 µg/L), MMF, prednisone, budesonide, methylprednisolone pulse (first of 3 consecutive days) | CsA (trough 67 µg/L), MMF, prednisone, budesonide |
| 3 | CsA (trough 84 µg/L), MMF | everolimus (trough 7.3 µg/L), MMF, prednisone | CsA (trough, 46 µg/L), MMF, prednisone |
| 4 | CsA (trough 103 µg/L) | CsA (trough 46 µg/L) | CsA (trough 46 µg/L) |
| 5 | MMF | MMF | None |
| 6 | CsA (trough 140 µg/L), MMF, prednisone | CsA (trough 101 µg/L), prednisone | None |
| 7 | Everolimus (trough 4.8 µg/L), MMF | None | None |
| 8 | Everolimus (trough 5.4 µg/L), MMF, prednisone | Everolimus (trough 4.3 µg/L), MMF, prednisone | Everolimus (trough 2.4 µg/L), MMF, prednisone, methylprednisolone pulse (second of 3 consecutive days), ruxolitinib |
| Patient Number . | Pharmacologic Immunosuppression . | . | . |
|---|---|---|---|
| . | At Start of AdV DNAemia . | At Start of Treatment With BCV . | At the End of Treatment With BCV . |
| 1 | None (already positive pretransplant) | CsA (trough 115 µg/L) | CsA (trough 97 µg/L), prednisone |
| 2 | CsA (trough 130 µg/L), MMF, budesonide, prednisone | CsA (trough 87 µg/L), MMF, prednisone, budesonide, methylprednisolone pulse (first of 3 consecutive days) | CsA (trough 67 µg/L), MMF, prednisone, budesonide |
| 3 | CsA (trough 84 µg/L), MMF | everolimus (trough 7.3 µg/L), MMF, prednisone | CsA (trough, 46 µg/L), MMF, prednisone |
| 4 | CsA (trough 103 µg/L) | CsA (trough 46 µg/L) | CsA (trough 46 µg/L) |
| 5 | MMF | MMF | None |
| 6 | CsA (trough 140 µg/L), MMF, prednisone | CsA (trough 101 µg/L), prednisone | None |
| 7 | Everolimus (trough 4.8 µg/L), MMF | None | None |
| 8 | Everolimus (trough 5.4 µg/L), MMF, prednisone | Everolimus (trough 4.3 µg/L), MMF, prednisone | Everolimus (trough 2.4 µg/L), MMF, prednisone, methylprednisolone pulse (second of 3 consecutive days), ruxolitinib |
Abbreviations: AdV, adenovirus; BCV, brincidofovir; CsA, cyclosporin A; MMF, mycophenolate mofetil.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
